

## PERSONAL INFORMATION

**Elena Torrisi** 95124 Catania (Italy)

Sex Female | Date of birth 18 Jan 1984 | Nationality Italian

## WORK EXPERIENCE

- 1 Jul 2019–Present **Medical doctor, Specialist in Oncology**  
ASP 5 Messina, Presidio Ospedaliero San Vincenzo, Taormina
- Jul 2018–Jun 2019 **Medical doctor, Specialist in Oncology**  
Centro di Riferimento Oncologico di Aviano, CRO-IRCCS
- Oct 2015–Jun 2018 **Medical Doctor, specialist in Oncology**  
AULSS Dolomiti 1 Belluno. Ospedale San Martino. Italy
- 16 Sep 2014–Sep 2015 **Medical research fellow**  
Centro di Riferimento Oncologico National Cancer Institute-CRO-IRCCS-Aviano. Medical Oncology B Dr. Angela Buonadonna and Sperimental Oncology 1, Dr Roberta Maestro.  
Medical treatment, clinical and preclinical research in gastrointestinal tumors ,sarcomas and rare tumors
- Jan 2013–Aug 2013 **Clinical fellow**  
Breast Unit, Royal Marsden Hospital, Fulham Road, Chelsea and Sutton. Prof. Ian Smith; Prof. Stephen Johnston., London (United Kingdom)  
Medical treatment and clinical research in Breast Cancer

## EDUCATION AND TRAINING

- 1 Jul 2009–1 Jul 2014 **Postgraduate diploma in medical oncology - Specialist in medical oncology** 70/70 cum laude  
Specialisation school in medical oncology, University of Catania
- Feb 2009 **Licence to practise medicine**  
Medical School, University of Catania  
National Exam for license to practise medicine  
Registration number CT13865
- 1 Oct 2002–24 Oct 2008 **Degree in Medicine and Surgery** 110/110 cum laude  
Medical School, University of Catania  
86, Via Santa Sofia, 95123 Catania (Italy)  
Experimental thesis on "Implications of the transcription factor Yin Yang 1 in the pathogenesis and progression of high grade non-Hodgkin lymphoma"
- Sep 1997–Jun 2002 **High school diploma in sciences** 100/100

Liceo scientifico Principe Umberto di Savoia, Catania

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C1	C1	C2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user  
Common European Framework of Reference for Languages

Communication skills - Good communication skills  
 - Good ability to adapt to multicultural environment  
 - Team spirit

Organisational / managerial skills Member of multidisciplinary teams (Breast Unit and Gastrointestinal tract and sarcomas Unit)

Job-related skills - Laboratory skills including cell culture, various assays.  
 - Management of oncological patients as outpatient and inpatient, medical division in: oncological therapy, adverse events, follow-up and supportive care.  
 - Management of Clinical trials

Digital skills - Good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™);

Driving licence A, B

ADDITIONAL INFORMATION

-From 2011 member of American Society of Clinical Oncology (ASCO) and Associazione Italiana di Oncologia Medica (AIOM)  
 -From 2013 member of European Society of Clinical Oncology (ESMO)  
 -Orally communication in Annual medical oncology national congress 2011 on Breast cancer datas.  
 -From 2009 volunteer member of the Lega Italiana per la lotta controitumori (LILT) Catania  
 -Research activity asco- investigator in various multicentre clinical trials and all of this were follow according to GCP  
 -From December 2012 fullregistration with licence to practise with the GMC (GeneralMedicalCouncil)  
 -Last GCP(Good clinical Practice)certificate April2013  
 -From October 2013 member of MITO group (Multicenter ItalianTrials in Ovarian cancer and gynecologic malignancies)  
 - November 2013 act as monitor to attest the good clinical prtise on MITO's clinical trial  
 - **Last ICH-GCP training 05 Sep18**

Publications Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Miolo G, Ash A, Buonadonna A, Lo Re G, **Torrisi E**, Cervo S, Santeufemia DA, Tuzi A, Canzonieri V. Cancer Biol Ther. 2014 Nov 2;15(11):1439-43  
 Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer? Lorusso D, Sarno I, Di Donato V, Palazzo A, **Torrisi E**, Pala L, Marchiano A, Raspagliesi F. Oncology. 2014;87(5):293-9.  
 Febrile neutropenia and cgemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer. Adjogats D, Thanopoulou E, Okines A, Thillai K,

- Tasker F, Johnston SR, Harper-Wynne C, **Torrisi E**, Ring A. Clin Oncol (R Coll Radiol). 2014 Jun 5. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. Gasparotto D, Miolo G, **Torrisi E**, Canzonieri V, Bertola G, Libra M, Marzotto A, Maestro R, Buonadonna A. Int J Colorectal Dis. 2014 May; 29(5):639-40.
- Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. Frustaci S, Buonadonna A, Turchet E, Corona G, Tabaro G, Miolo G, **Torrisi E**, Lo Re G, Tumolo S, Toffoli G. Int J Clin Oncol. 2013 Jun; 18(3):510-6.
- Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients :Retrospective Analysis of Our Series. Di Lauro V, **Torrisi E**, Bidoli E, Quitadamo D, Cecco S, Veronesi A. J Oncol. 2012;2012:198412.
- Lapatinib-based therapy in heavily pretreated HER2- positive metastatic breast cancer: a single institution experience. Crivellari D, Spazzapan S, Lombardi D, Militello L, **Torrisi E**, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A. Tumori. 2012 Jan-Feb;98(1):33-8.
- Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, **Torrisi E**, Crivellari D. Ann Oncol. 2012 Jun; 23(6):1436-41.
- Yin-Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B- cell transformation and tumor progression. Castellano G, **Torrisi E**, Ligresti G, Nicoletti F, Malaponte G, Travali S, McCubrey JA, Canevari S, Libra M. Cell Cycle. 2010 Feb 1; 9(3):557-63.
- Melanoma: molecular pathogenesis and emerging target therapies (Review). Russo AE, **Torrisi E**, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G. Int J Oncol. 2009 Jun; 34(6):1481-9. Review.
- BRAF and RAS aberrations in actinic keratosis and non-melanoma skin cancers. Libra M, **Torrisi E**. Cell Cycle. 2009 May; 8(9):1305.
- The involvement of the transcription factor YinYang1 in cancer development and progression. Castellano G, **Torrisi E**, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. Cell Cycle. 2009 May 1; 8(9):1367-72.

"I consent to the use of my personal data, in accordance with the current law (Reg UE 679/2016 – Regolamento Generale sulla Protezione dei Dati -"GDPR")"